I期高实性占比及实性肺腺癌患者诊断–手术时间间隔对患者预后的影响
The Effect of Diagnosis-Surgery Interval on the Prognosis of Patients with High Solid Proportion or Solid Stage I Lung Adenocarcinoma
摘要: 目的:探究诊断–手术时间间隔对I期部分实性或实性密度结节肺腺癌患者预后的影响,并分析其与术后病理高危因素之间的关系。方法:通过回顾性分析2018年6月至2019年6月I期肺腺癌患者的临床数据,采用RCS方法探究手术间隔时间与生存结果之间的关系,以RCS图线中拐点为分界,将患者分为A组(n = 293)与B组(n = 234),采用Kaplan-Meier法绘制生存曲线评估二组差异,采用倾向性得分匹配后控制变量后重复Kaplan-Meier法绘制生存曲线。通过Wilcoxon秩和检验评估两组手术时间、住院时间及带管时间是否存在差异。采用Logistic回归分析,探讨诊断–手术时间间隔与病理高危因素之间的关联性。结果:共收集527例临床诊断为I期的肺腺癌患者,RCS图示拐点为8周,患者复发风险8周后都随诊断–手术时间间隔的延长而增加。诊断时间间隔与DFS行单因素COX分析得,二者之间存在相关(HR, 1.57, 95% CI, 0.95~2.59, P = 0.076)。倾向性得分匹配后可见A组无病生存期及总生存期都强于B组,且存在统计学意义。诊断–手术间隔时间延长会导致脉管癌栓出现的可能性增加(OR 2.35, 95% CI, 1.01~5.47, P = 0.048),对胸膜侵犯(OR, 1.226, 95% CI, 0.485~3.099, P = 0.667)及气道播散(OR, 1.247, 95% CI, 0.631~2.465, P = 0.526)的出现与否的影响无统计学意义。结论:诊断–手术时间间隔超过8周会导致患者远期预后不良。诊断–手术间隔的延长可能会导致脉管癌栓出现,从而影响患者远期预后。
Abstract: Objective: To investigate the impact of the diagnosis-to-surgery interval (DSI) on the prognosis of patients with stage I lung adenocarcinoma presenting as part-solid or solid density nodules and analyze its association with postoperative pathological high-risk factors. Methods: By retrospectively analyzing the clinical data of stage I lung adenocarcinoma patients from June 2018 to June 2019, the relationship between the surgery interval and survival outcomes was investigated using the RCS method. Patients were divided into group A (n = 293) and group B (n = 234) based on the inflection point in the RCS graph. Survival curves were plotted using the Kaplan-Meier method to assess the differences between the two groups. The Kaplan-Meier method was repeated after propensity score matching to control for variables. The Wilcoxon rank sum test was used to evaluate whether there were differences in the operation time, hospital stay, and tube retention time between the two groups. Logistic regression analysis was used to explore the association between the diagnosis-surgery interval and pathological high-risk factors. Results: A total of 527 patients with stage I lung adenocarcinoma were collected. The inflection point in the RCS graph was 8 weeks, and the recurrence risk increased with the extension of the diagnosis-surgery interval after 8 weeks. Univariate COX analysis of the diagnosis-surgery interval and disease-free survival showed a correlation between the two (HR, 1.57, 95% CI, 0.95~2.59, P = 0.076). After propensity score matching, it was observed that the disease-free survival and overall survival of group A were better than those of group B. An extended diagnosis-surgery interval increased the possibility of vascular tumor thrombus (OR 2.35, 95% CI, 1.01~5.47, P = 0.048), but had no statistically significant impact on the occurrence of pleural invasion(OR, 1.226, 95% CI, 0.485~3.099, P = 0.667) or airway dissemination (OR, 1.247, 95% CI, 0.631~2.465, P = 0.526). Conclusion: A diagnosis-surgery interval exceeding 8 weeks may lead to poor long-term prognosis in patients. An extended diagnosis-surgery interval may increase the occurrence of vascular tumor thrombus, which may be the reason for the poor long-term prognosis of patients.
文章引用:周亮, 刘汉群, 赵策, 王子成, 金翔凤, 矫文捷. I期高实性占比及实性肺腺癌患者诊断–手术时间间隔对患者预后的影响[J]. 临床医学进展, 2025, 15(5): 1642-1653. https://doi.org/10.12677/acm.2025.1551538

参考文献

[1] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[2] Wu, L.L. (2020) Association between Number of Dissected Lymph Nodes and Survival in Stage IA Non-Small Cell Lung Cancer: A Propensity Score Matching Analysis. World Journal of Surgical Oncology, 18, Article No. 322.
[3] Oncology Society of Chinese Medical Association (2024) [Chinese Medical Association Guideline for Clinical Diagnosis and Treatment of Lung Cancer (2024 Edition)]. Chinese Journal of Oncology, 46, 805-843.
[4] de Koning, H.J., et al. (2020) Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. The New England Journal of Medicine, 382, 503-513.
[5] Tupper, H.I., Sarovar, V., Banks, K.C., Schmittdiel, J.A., Hsu, D.S., Ashiku, S.K., et al. (2024) Time to Surgery in Early-Stage Non-Small Cell Lung Cancer: Defining the Optimal Diagnosis-To-Resection Interval to Reduce Mortality. The Journal of Thoracic and Cardiovascular Surgery. [Google Scholar] [CrossRef] [PubMed]
[6] Abrao, F.C., de Abreu, I.R.L.B., Rocha, R.O., Munhoz, F.D., Rodrigues, J.H.G. and Batista, B.N. (2018) Interaction between Treatment Delivery Delay and Stage on the Mortality from Non-Small Cell Lung Cancer. Journal of Thoracic Disease, 10, 2813-2819. [Google Scholar] [CrossRef] [PubMed]
[7] Barcelos, R.R., Sugarbaker, E., Kennedy, K.F., McAllister, M., Kim, S., Herrera-Zamora, J., et al. (2024) Time between Imaging and Surgery Is Not a Risk Factor for Upstaging of Clinical Stage IA Non-Small-Cell Lung Cancer. European Journal of Cardio-Thoracic Surgery, 65, ezae057. [Google Scholar] [CrossRef] [PubMed]
[8] Diaconescu, R., Lafond, C. and Whittom, R. (2011) Treatment Delays in Non-Small Cell Lung Cancer and Their Prognostic Implications. Journal of Thoracic Oncology, 6, 1254-1259. [Google Scholar] [CrossRef] [PubMed]
[9] Tang, A., Ahmad, U., Raja, S., Bribriesco, A.C., Sudarshan, M., Rappaport, J., et al. (2021) How Much Delay Matters? How Time to Treatment Impacts Overall Survival in Early Stage Lung Cancer. Annals of Surgery, 277, e941-e947. [Google Scholar] [CrossRef] [PubMed]
[10] Banks, K.C., Dusendang, J.R., Schmittdiel, J.A., Hsu, D.S., Ashiku, S.K., Patel, A.R., et al. (2023) Association of Surgical Timing with Outcomes in Early Stage Lung Cancer. World Journal of Surgery, 47, 1323-1332. [Google Scholar] [CrossRef] [PubMed]
[11] Samson, P., Patel, A., Garrett, T., Crabtree, T., Kreisel, D., Krupnick, A.S., et al. (2015) Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery, 99, 1906-1913. [Google Scholar] [CrossRef] [PubMed]
[12] Maiga, A.W., Deppen, S.A., Pinkerman, R., Callaway-Lane, C., Massion, P.P., Dittus, R.S., et al. (2017) Timeliness of Care and Lung Cancer Tumor-Stage Progression: How Long Can We Wait? The Annals of Thoracic Surgery, 104, 1791-1797. [Google Scholar] [CrossRef] [PubMed]
[13] Ha, D., Ries, A.L., Montgrain, P., Vaida, F., Sheinkman, S. and Fuster, M.M. (2018) Time to Treatment and Survival in Veterans with Lung Cancer Eligible for Curative Intent Therapy. Respiratory Medicine, 141, 172-179. [Google Scholar] [CrossRef] [PubMed]
[14] Coughlin, S., Plourde, M., Guidolin, K., Fortin, D., Frechette, E., Malthaner, R., et al. (2015) Is It Safe to Wait? The Effect of Surgical Wait Time on Survival in Patients with Non-Small Cell Lung Cancer. Canadian Journal of Surgery, 58, 414-418. [Google Scholar] [CrossRef] [PubMed]
[15] Gomez, D.R., et al. (2015) Time to Treatment as a Quality Metric in Lung Cancer: Staging Studies, Time to Treatment, and Patient Survival. Radiotherapy and Oncology, 115, 257-263.
[16] Jacobsen, M.M., Silverstein, S.C., Quinn, M., Waterston, L.B., Thomas, C.A., Benneyan, J.C., et al. (2017) Timeliness of Access to Lung Cancer Diagnosis and Treatment: A Scoping Literature Review. Lung Cancer, 112, 156-164. [Google Scholar] [CrossRef] [PubMed]
[17] Heiden, B.T., Eaton, D.B., Engelhardt, K.E., Chang, S., Yan, Y., Patel, M.R., et al. (2021) Analysis of Delayed Surgical Treatment and Oncologic Outcomes in Clinical Stage I Non-Small Cell Lung Cancer. JAMA Network Open, 4, e2111613. [Google Scholar] [CrossRef] [PubMed]
[18] McPherson, I., Bradley, N.A., Govindraj, R., Kennedy, E.D., Kirk, A.J.B. and Asif, M. (2020) The Progression of Non-Small Cell Lung Cancer from Diagnosis to Surgery. European Journal of Surgical Oncology, 46, 1882-1887. [Google Scholar] [CrossRef] [PubMed]
[19] Stiles, B.M., Servais, E.L., Lee, P.C., Port, J.L., Paul, S. and Altorki, N.K. (2009) POINT: Clinical Stage IA Non-Small Cell Lung Cancer Determined by Computed Tomography and Positron Emission Tomography Is Frequently Not Pathologic IA Non-Small Cell Lung Cancer: The Problem of Understaging. The Journal of Thoracic and Cardiovascular Surgery, 137, 13-19. [Google Scholar] [CrossRef] [PubMed]
[20] McLaughlin, J.M., Anderson, R.T., Ferketich, A.K., Seiber, E.E., Balkrishnan, R. and Paskett, E.D. (2012) Effect on Survival of Longer Intervals between Confirmed Diagnosis and Treatment Initiation among Low-Income Women with Breast Cancer. Journal of Clinical Oncology, 30, 4493-4500. [Google Scholar] [CrossRef] [PubMed]
[21] Tang, E., Chen, C., Wu, C.C., Wu, M., Yang, T., Liang, H., et al. (2019) Natural History of Persistent Pulmonary Subsolid Nodules: Long-Term Observation of Different Interval Growth. Heart, Lung and Circulation, 28, 1747-1754. [Google Scholar] [CrossRef] [PubMed]
[22] Kuroda, H., Mori, S., Tanaka, H., Yoshida, T., Mizuno, T., Sakakura, N., et al. (2017) Prognostic Significance of Combined Radiologic Imaging Modalities for Prognosis of Clinical IA Adenocarcinomas. Oncotarget, 9, 10745-10753. [Google Scholar] [CrossRef] [PubMed]
[23] Sakakura, N., Inaba, Y., Yatabe, Y., Mizuno, T., Kuroda, H., Yoshimura, K., et al. (2016) Estimation of the Pathological Invasive Size of Pulmonary Adenocarcinoma Using High-Resolution Computed Tomography of the Chest: A Consideration Based on Lung and Mediastinal Window Settings. Lung Cancer, 95, 51-56. [Google Scholar] [CrossRef] [PubMed]
[24] Islam, K.M.M., Jiang, X., Anggondowati, T., Lin, G. and Ganti, A.K. (2015) Comorbidity and Survival in Lung Cancer Patients. Cancer Epidemiology, Biomarkers & Prevention, 24, 1079-1085. [Google Scholar] [CrossRef] [PubMed]
[25] Han, K., Kim, W., Song, A., Ju, Y.J., Choi, D. and Kim, S. (2021) Is Time-To-Treatment Associated with Higher Mortality in Korean Elderly Lung Cancer Patients? Health Policy, 125, 1047-1053. [Google Scholar] [CrossRef] [PubMed]
[26] Herndon, J.E. and Harrell, F.E. (1995) The Restricted Cubic Spline as Baseline Hazard in the Proportional Hazards Model with Step Function Time‐dependent Covariables. Statistics in Medicine, 14, 2119-2129. [Google Scholar] [CrossRef] [PubMed]
[27] Khorana, A.A., Tullio, K., Elson, P., Pennell, N.A., Grobmyer, S.R., Kalady, M.F., et al. (2019) Time to Initial Cancer Treatment in the United States and Association with Survival over Time: An Observational Study. PLOS ONE, 14, e0213209. [Google Scholar] [CrossRef] [PubMed]
[28] Kanarek, N.F., Hooker, C.M., Mathieu, L., Tsai, H., Rudin, C.M., Herman, J.G., et al. (2014) Survival after Community Diagnosis of Early-Stage Non-Small Cell Lung Cancer. The American Journal of Medicine, 127, 443-449. [Google Scholar] [CrossRef] [PubMed]
[29] Tørring, M.L., Frydenberg, M., Hansen, R.P., Olesen, F. and Vedsted, P. (2013) Evidence of Increasing Mortality with Longer Diagnostic Intervals for Five Common Cancers: A Cohort Study in Primary Care. European Journal of Cancer, 49, 2187-2198. [Google Scholar] [CrossRef] [PubMed]
[30] Singal, G., Miller, P.G., Agarwala, V., Li, G., Kaushik, G., Backenroth, D., et al. (2019) Association of Patient Characteristics and Tumor Genomics with Clinical Outcomes among Patients with Non-Small Cell Lung Cancer Using a Clinicogenomic Database. JAMA, 321, 1391-1399. [Google Scholar] [CrossRef] [PubMed]